Common Equity: The sum of all common equity items.
Myriad Genetics, Inc. (MYGN) had Common Equity of $372.80M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$205.70M |
|
$-27.40M |
|
$61.90M |
|
$143.80M |
|
$229.00M |
|
$-23.30M |
|
$-2.90M |
|
$-26.20M |
|
$-26.20M |
|
$-27.40M |
|
$-27.40M |
|
$-27.40M |
|
$-27.40M |
|
$-23.30M |
|
$-10.70M |
|
93.10M |
|
93.10M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$344.80M |
|
$111.40M |
|
$383.30M |
|
$728.10M |
|
$148.00M |
|
$119.50M |
|
$207.30M |
|
$355.30M |
|
|
Common Equity |
$372.80M |
$158.10M |
|
$372.80M |
|
93.10M |
|
| Cash Flow Statement Financials | |
$-8.80M |
|
$-21.40M |
|
$72.40M |
|
$111.90M |
|
$154.80M |
|
$42.90M |
|
$32.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.33 |
|
-- |
|
-- |
|
0.24 |
|
0.32 |
|
69.91% |
|
-11.33% |
|
-11.33% |
|
-- |
|
-12.74% |
|
-13.32% |
|
$-19.70M |
|
-- |
|
-- |
|
-- |
|
0.28 |
|
1.96 |
|
1.74 |
|
51.63 |
|
-7.35% |
|
-17.33% |
|
-3.76% |
|
-5.57% |
|
$4.00 |
|
$-0.21 |
|
$-0.09 |
|